Article
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Molecular cancer therapeutics - 1 Aug 2023
Ghosh Susmita, Fan Fan, Powell Reid T, Roszik Jason, Park Yong Sung, Stephan Clifford, Sebastian Manu, Tan Lin, Sorokin Alexey V, Lorenzi Philip L, Kopetz Scott, Ellis Lee M, Bhattacharya Rajat
Abstract excerpt
Mutations in KRAS are found in more than 50% of tumors from patients with metastatic colorectal cancer (mCRC). However, direct targeting of most KRAS mutations is difficult; even the recently developed KRASG12C inhibitors failed to show significant benefit in patients with mCRC. Single agents targeting mitogen-activated protein kinase kinase (MEK), a downstream mediator of RAS, have also been ineffective in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.